Asia
Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action.
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
Strongly supporting companies and regional authorities that seek to provide new services for healthy, more fulfilling lifestyles
Israel-based Teva Pharmaceutical is the largest generic drug company in the world. One in 10 drugs taken in the U.S. are manufactured by Teva, but as generic drug prices are forced downward, the company has struggled.
Eisai Co., Ltd. announced that it has submitted an application to the European Medicines Agency for its in-house discovered antiepileptic drug Fycompa seeking approval for use in pediatric patients with epilepsy.
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
When biotech companies post openings for new positions, hiring managers often face the immense task of sorting through numerous resumes of qualified candidates. However, in South Korea, hiring managers are facing a different problem – a dearth of qualified candidates.
When the U.S. Food and Drug Administration approved Genentech’s Xofluza, a single-dose treatment for the flu, it was met with great fanfare, particularly in Japan, where the treatment was first discovered.
Hitachi, Ltd., Jichi Medical University, International University of Health and Welfare and Chuo University have developed fundamental technology to support the early differential diagnosis of concurrent autism spectrum disorder in patients with attention-deficit hyperactivity disorder.
PRESS RELEASES